RLAY vs. ALLO, FATE, VIR, FPRX, SWTX, ACLX, APGE, DNLI, IOVA, and IMCR
Should you be buying Relay Therapeutics stock or one of its competitors? The main competitors of Relay Therapeutics include Allogene Therapeutics (ALLO), Fate Therapeutics (FATE), Vir Biotechnology (VIR), Five Prime Therapeutics (FPRX), SpringWorks Therapeutics (SWTX), Arcellx (ACLX), Apogee Therapeutics (APGE), Denali Therapeutics (DNLI), Iovance Biotherapeutics (IOVA), and Immunocore (IMCR). These companies are all part of the "medical" sector.
Relay Therapeutics (NASDAQ:RLAY) and Allogene Therapeutics (NASDAQ:ALLO) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, earnings, media sentiment, valuation, institutional ownership, dividends, community ranking, analyst recommendations and profitability.
In the previous week, Relay Therapeutics and Relay Therapeutics both had 15 articles in the media. Allogene Therapeutics' average media sentiment score of 0.89 beat Relay Therapeutics' score of 0.75 indicating that Allogene Therapeutics is being referred to more favorably in the news media.
Relay Therapeutics has a net margin of -1,263.49% compared to Allogene Therapeutics' net margin of -223,139.98%. Relay Therapeutics' return on equity of -42.66% beat Allogene Therapeutics' return on equity.
97.0% of Relay Therapeutics shares are owned by institutional investors. Comparatively, 83.6% of Allogene Therapeutics shares are owned by institutional investors. 4.3% of Relay Therapeutics shares are owned by company insiders. Comparatively, 24.3% of Allogene Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Allogene Therapeutics received 231 more outperform votes than Relay Therapeutics when rated by MarketBeat users. Likewise, 64.83% of users gave Allogene Therapeutics an outperform vote while only 61.54% of users gave Relay Therapeutics an outperform vote.
Relay Therapeutics has a beta of 1.66, indicating that its stock price is 66% more volatile than the S&P 500. Comparatively, Allogene Therapeutics has a beta of 0.86, indicating that its stock price is 14% less volatile than the S&P 500.
Relay Therapeutics presently has a consensus price target of $22.80, suggesting a potential upside of 210.63%. Allogene Therapeutics has a consensus price target of $9.95, suggesting a potential upside of 318.07%. Given Allogene Therapeutics' higher possible upside, analysts clearly believe Allogene Therapeutics is more favorable than Relay Therapeutics.
Allogene Therapeutics has lower revenue, but higher earnings than Relay Therapeutics. Relay Therapeutics is trading at a lower price-to-earnings ratio than Allogene Therapeutics, indicating that it is currently the more affordable of the two stocks.
Summary
Allogene Therapeutics beats Relay Therapeutics on 9 of the 16 factors compared between the two stocks.
Get Relay Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for RLAY and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding RLAY and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Relay Therapeutics Competitors List
Related Companies and Tools
